ABSTRACT
Introduction: the aim of this study was to investigate the effects of turmeric consumption on serum levels of ICAM, iron, ferritin and the total iron binding capacity [TIBC] as cardiovascular risk factors in patients with non-alcoholic fatty liver disease [NAFLD]
Material and Methods: a randomized, double blind controlled clinical trial was conducted on 46 NAFLD patients who were referred to a gastroenterologist and diagnosed with liver ultrasonography. The subjects were assigned into two groups, experimental [n=23] and placebo [n=23]. The experimental group received 6 capsules containing 500 mg turmeric and the control group received the same number of placebo capsules for 12 weeks. Anthropometric measurements, dietary intake and blood biochemical parameters were assessed at the beginning and at the end of the study. Data were analyzed by Independent t-test, Paired t-test and ANCOVA
Results: there were no statistically significant differences in age, sex, body mass index, daily energy intakes and echogenicity of liver between the two groups at the beginning. The level of ICAM in the experimental group significantly decreased at the end of the study compared to the beginning [P=0.001]. Turmeric consumption significantly decreased serum ferritin levels at the end of the study compared to control group [P=0.026]
Conclusion: the results of this study showed that turmeric consumption has beneficial effects on serum levels of ICAM and ferritin in individuals with NAFLD and most likely is effective in controlling the risk factors of this disease